Insider Trading April 3, 2026

Neuraxis CEO Makes Small Equity Purchase as Company Posts Mixed Q4 Results

Brian Allen Carrico adds 8,060 shares to his stake; revenue rises but net loss and margin pressures persist

By Sofia Navarro NRXS
Neuraxis CEO Makes Small Equity Purchase as Company Posts Mixed Q4 Results
NRXS

Neuraxis, INC Chief Executive Officer Brian Allen Carrico acquired 8,060 shares of the company’s common stock on April 1, 2026, at $1.96 per share for a total of $15,797. Following the trade he directly holds 348,178 shares. Since that purchase, the stock has climbed to $7.25, a near 270% increase from his buy price, and the company's market capitalization sits at $81.11 million. Separately, NeurAxis reported fourth-quarter 2025 revenue growth of 27% to $968,000 but posted a net loss of $1.7 million and saw gross margin compress by 100 basis points amid inventory issues and the rollout of a lower-margin product. InvestingPro data shows a 272% return for NRXS over the past year, though the platform's Fair Value analysis flags potential overvaluation.

Key Points

  • CEO Brian Allen Carrico purchased 8,060 shares on April 1, 2026 at $1.96 per share, totaling $15,797; he now directly owns 348,178 shares.
  • Shares have since risen to $7.25, about a 270% increase from Carrico's purchase price; market capitalization is $81.11 million. InvestingPro data shows a 272% return over the past year, but its Fair Value analysis flags possible overvaluation.
  • NeurAxis reported Q4 2025 revenue of $968,000, up 27% year-over-year, while posting a net loss of $1.7 million and a 100 basis point decline in gross margin due to inventory issues and a lower-margin product.

Insider transaction

Neuraxis, INC (NRXS) Chief Executive Officer Brian Allen Carrico reported a purchase of 8,060 shares of the company's common stock on April 1, 2026. The shares were acquired at $1.96 each, bringing the total transaction value to $15,797. After the transaction, Carrico directly owns 348,178 shares of Neuraxis, INC.


Share performance since purchase

The timing of Carrico's buy preceded a substantial uptick in the stock price. Shares have since reached $7.25, which represents nearly a 270% increase relative to his $1.96 purchase price. The company’s market capitalization is now reported at $81.11 million.


Recent trading and valuation context

According to InvestingPro data cited in company-related summaries, NRXS has returned roughly 272% over the past year. That same source’s Fair Value analysis indicates the stock may be trading above its fair value at present. The InvestingPro platform is reported to offer an additional 12 tips for subscribers seeking deeper insight into NRXS.


Quarterly financial results

In its fourth quarter of 2025, NeurAxis reported revenue of $968,000, an increase of 27% compared with the same quarter a year earlier. Despite the top-line growth, the company recorded a net loss of $1.7 million in the period, slightly wider than the $1.5 million loss reported in the comparable quarter of the prior year.

Management attributed a 100 basis point decline in gross margin to inventory challenges and the introduction of a lower-margin product. Those factors contributed to the mix of results that combine revenue improvement with margin and profitability pressures.


Investor considerations

The recent combination of insider buying, strong short-term share appreciation, and mixed financial metrics has drawn attention from investors and analysts. Stakeholders are said to be monitoring the company's ability to manage costs and product margins, given the juxtaposition of revenue growth and continued net losses. Specific intraday or other short-term stock price movements are not detailed in the available disclosures.


Note: The article presents the transaction, market data, and the company's reported quarterly financials as publicly disclosed. Where detail is limited in the disclosures, those limitations are reflected here rather than supplemented with additional information.

Risks

  • Profitability risk - the company recorded a net loss of $1.7 million in Q4 2025, slightly wider than the prior-year loss, indicating continued challenges toward consistent profitability - impacts investors and equity markets.
  • Margin pressure - a 100 basis point decline in gross margin was attributed to inventory challenges and the introduction of a lower-margin product, affecting product economics and potentially operating cash flows - impacts company operational performance and supplier/production sectors.
  • Valuation uncertainty - InvestingPro's Fair Value analysis suggests NRXS may be overvalued despite strong recent returns, creating potential downside for investors if market expectations recalibrate - impacts equity valuation and investor sentiment.

More from Insider Trading

A.K.A. Brands Director Disposes of $157,270 in Stock; Company Sales Meet Guidance Apr 3, 2026 Neuraxis CFO Purchases $14,882 of Company Stock as Shares Rally Apr 3, 2026 Neuraxis Insider Carrico Acquires 667 Shares as Company Posts Q4 Revenue Gain and Margin Pressure Apr 3, 2026 Director McClure Sells 1,081 Horace Mann Shares Under 10b5-1 Plan; Company Posts Strong Q4 Results Apr 3, 2026 Japan Post Trims Aflac Stake in $2.15 Million Sale Apr 3, 2026